Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate achievement ratio of treatment target goal in hypercholesterolemia patients with high risk after high dose rosuvastatin(20mg/day) titration
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Inclusion Criteria:
High-risk hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on the physician's clinical decision and fulfill the following criteria
Exclusion Criteria:
Not provided
Not provided
Not provided
Hypercholesteromia patients with high risk according to NCEP ATP III guideline in Korean tertiary care centers
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hyunah Caroline Choi | AstraZeneca Korea | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Seoul | Jongro-gu | South Korea | |||
| Research Site |
Not provided
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Seoul |
| Kangnam-gu |
| South Korea |
| Research Site | Seoul | Songpa-gu | South Korea |
| D009750 |
| Nutritional and Metabolic Diseases |